Rilzabrutinib

123 interactions 11 explained in plain English

Also sold as: Wayrilz

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Letermovir Injection Ketoconazole Topical Famotidine Injection Dexlansoprazole Encorafenib Nizatidine

18 Major 105 Moderate

All (123) Major (18) Moderate (105)

Moderate

Rilzabrutinib Ivabradine Corlanor Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Ixazomib Ninlaro Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Leniolisib Joenja Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Levothyroxine Ermeza Increased risk of hypothyroidism Details Rilzabrutinib Linagliptin Tradjenta Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Loperamide Diamode Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Loratadine Agistam® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Lovastatin Altocor® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Lumateperone Caplyta Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Lurasidone Latuda Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Lurbinectedin Injection Zepzelca Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Macitentan Opsumit Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Maraviroc Selzentry Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Midazolam Nasal Spray Nayzilam Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Midazolam Injection Nayzilam Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Midostaurin Rydapt Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Naldemedine Symproic Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Naloxegol Movantik Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Nateglinide Starlix® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Neratinib Nerlynx Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Nevirapine Viramune Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Nifedipine Adalat® Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Nintedanib Ofev Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Nisoldipine Sular Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details Rilzabrutinib Olaparib Lynparza Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.